Abbott Laboratories (ABT)
3 Dividend Growth Stocks to Buy Hand Over Fist in August
Abbott Labs is a proven wealth builder at a fair price. Johnson & Johnson's a safe buy despite its ongoing litigation.
Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Abbott Laboratories is now a $183 billion (by market cap) healthcare titan. Abbott Laboratories has increased its dividend for more than 50 consecutive years. So it has the kind of dividend growth pedigree that few companies can compare to. The company has increased its revenue from $20.2 billion in FY 2014 to $40.1 billion in FY 2023. That's a solid compound annual growth rate of 7.9%.
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off
Abbott Laboratories and Gilead Sciences are solid dividend stocks. Both look a bit pricey relative to their recent financial results.
Abbott (ABT) Just Overtook the 200-Day Moving Average
Abbott (ABT) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ABT broke through the 200-day moving average, which suggests a long-term bullish trend.
As Diabetes Battle Heats Up, Spotlight Turns To Dexcom, Abbott
The diabetes donnybrook between Abbott Laboratories and Dexcom is poised to heat up — and could bolster both Abbott stock and Dexcom stock.
Forget Johnson & Johnson: Another Healthcare Giant Is a Much Better Bet for Growth
Johnson & Johnson has been generating decent growth, but legal challenges could create a lot of uncertainty. Abbott Laboratories has a more diverse business, with some exciting opportunities in diabetes care.
7 Leading MedTech Stocks for Next-Gen Health Solutions
While technology lately has been framed in the context of computer hardware or software, it can also apply to the broader field of medicine. Therefore, investors should consider the viable field of MedTech stocks.
My Best Dividend Aristocrats For August 2024
The ProShares S&P 500 Dividend Aristocrats ETF slumps to end the first half of 2024, posting a loss of 1.40% in June. I present 3 strategies that can theoretically beat the dividend aristocrat index in the long term. After 36 months of tracking these strategies, two strategies are outperforming NOBL, while 1 remains relatively close.
Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Abbott Stock Slips After Company Ordered to Pay $495 Million in Baby Formula Case
Shares of Abbott Laboratories (ABT) came under pressure Monday after a jury in St. Louis late Friday ordered the company to pay $495 million in compensation and damages in a lawsuit over the company's specialized formula for premature babies.
Trial Defeat, Resistance Level Drags Abbott Stock
Abbott Laboratories (NYSE:ABT)) is off 3.6% to trade at $101.44 this morning, suffering a drop after its premature infant formula trial ended in the company needing to pay $495 million in damages to those impacted by a possible increase in bowel disease.
10 Beaten-Up Blue Chips With Serious Turnaround Potential
Here is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.
